APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Vaginal Fungi Infections Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Vaginal Fungi Infections Treatment Market Outlook and Growth Opportunities 2026

Report ID 174044910419 December 2025197 pages

Choose your research edition.

Industry ResearchVaginal Fungi Infections Treatment Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Vaginal Fungi Infections Treatment Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Vaginal Fungi Infections Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vaginal Fungi Infections Treatment Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Vaginal Fungi Infections Treatment Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Vaginal Fungi Infections Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Vaginal Fungi Infections Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vaginal Fungi Infections Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vaginal Fungi Infections Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Vaginal Fungi Infections Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Vaginal Fungi Infections Treatment market include ANI Pharmaceuticals, Aurobindo Pharma Limited, Bausch Health Companies Inc, Dr. Reddy's Laboratories, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals Plc, Lupin Limited, Mycovia Pharmaceuticals and PEPTONIC medical AB, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Vaginal Fungi Infections Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vaginal Fungi Infections Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vaginal Fungi Infections Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Vaginal Fungi Infections Treatment market.

Vaginal Fungi Infections Treatment Segment by Company

ANI Pharmaceuticals

Aurobindo Pharma Limited

Bausch Health Companies Inc

Dr. Reddy's Laboratories

Glenmark Pharmaceuticals Limited

Hikma Pharmaceuticals Plc

Lupin Limited

Mycovia Pharmaceuticals

PEPTONIC medical AB

SCYNEXIS

Unique Pharmaceuticals

Pfizer Inc.

Vaginal Fungi Infections Treatment Segment by Type

Flucytosine

Fluconazole

Nystatin

Others

Vaginal Fungi Infections Treatment Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Vaginal Fungi Infections Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Vaginal Fungi Infections Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Vaginal Fungi Infections Treatment key companies, revenue, market share, and recent developments.

3. To split the Vaginal Fungi Infections Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Vaginal Fungi Infections Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Vaginal Fungi Infections Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Vaginal Fungi Infections Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaginal Fungi Infections Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vaginal Fungi Infections Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaginal Fungi Infections Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Vaginal Fungi Infections Treatment industry.

Chapter 3: Detailed analysis of Vaginal Fungi Infections Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Vaginal Fungi Infections Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Vaginal Fungi Infections Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Vaginal Fungi Infections Treatment Industry Trends Table 2. Vaginal Fungi Infections Treatment Industry Drivers Table 3. Vaginal Fungi Infections Treatment Industry Opportunities and Challenges Table 4. Vaginal Fungi Infections Treatment Industry Restraints Table 5. Global Vaginal Fungi Infections Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Vaginal Fungi Infections Treatment Revenue Share by Company (2021-2026) Table 7. Global Vaginal Fungi Infections Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Vaginal Fungi Infections Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Vaginal Fungi Infections Treatment Company, Product Type & Application Table 10. Global Vaginal Fungi Infections Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Vaginal Fungi Infections Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Flucytosine Table 15. Significant Companies of Fluconazole Table 16. Significant Companies of Nystatin Table 17. Significant Companies of Others Table 18. Global Vaginal Fungi Infections Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Vaginal Fungi Infections Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Vaginal Fungi Infections Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Vaginal Fungi Infections Treatment Sales Value Share by Type (2021-2026) Table 22. Global Vaginal Fungi Infections Treatment Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Pharmacies Table 24. Significant Companies of Online Pharmacies Table 25. Significant Companies of Retail Pharmacies Table 26. Global Vaginal Fungi Infections Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Vaginal Fungi Infections Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Vaginal Fungi Infections Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Vaginal Fungi Infections Treatment Sales Value Share by Application (2021-2026) Table 30. Global Vaginal Fungi Infections Treatment Sales Value Share by Application (2027-2032) Table 31. Global Vaginal Fungi Infections Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Vaginal Fungi Infections Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Vaginal Fungi Infections Treatment Sales Value Share by Region (2021-2026) Table 34. Global Vaginal Fungi Infections Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Vaginal Fungi Infections Treatment Sales Value Share by Region (2027-2032) Table 36. Global Vaginal Fungi Infections Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Vaginal Fungi Infections Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Vaginal Fungi Infections Treatment Sales Value Market Share by Country (2021-2026) Table 39. Global Vaginal Fungi Infections Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Vaginal Fungi Infections Treatment Sales Value Market Share by Country (2027-2032) Table 41. ANI Pharmaceuticals Company Information Table 42. ANI Pharmaceuticals Business Overview Table 43. ANI Pharmaceuticals Vaginal Fungi Infections Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. ANI Pharmaceuticals Vaginal Fungi Infections Treatment Product Portfolio Table 45. ANI Pharmaceuticals Recent Development Table 46. Aurobindo Pharma Limited Company Information Table 47. Aurobindo Pharma Limited Business Overview Table 48. Aurobindo Pharma Limited Vaginal Fungi Infections Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Aurobindo Pharma Limited Vaginal Fungi Infections Treatment Product Portfolio Table 50. Aurobindo Pharma Limited Recent Development Table 51. Bausch Health Companies Inc Company Information Table 52. Bausch Health Companies Inc Business Overview Table 53. Bausch Health Companies Inc Vaginal Fungi Infections Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Bausch Health Companies Inc Vaginal Fungi Infections Treatment Product Portfolio Table 55. Bausch Health Companies Inc Recent Development Table 56. Dr. Reddy's Laboratories Company Information Table 57. Dr. Reddy's Laboratories Business Overview Table 58. Dr. Reddy's Laboratories Vaginal Fungi Infections Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Dr. Reddy's Laboratories Vaginal Fungi Infections Treatment Product Portfolio Table 60. Dr. Reddy's Laboratories Recent Development Table 61. Glenmark Pharmaceuticals Limited Company Information Table 62. Glenmark Pharmaceuticals Limited Business Overview Table 63. Glenmark Pharmaceuticals Limited Vaginal Fungi Infections Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Glenmark Pharmaceuticals Limited Vaginal Fungi Infections Treatment Product Portfolio Table 65. Glenmark Pharmaceuticals Limited Recent Development Table 66. Hikma Pharmaceuticals Plc Company Information Table 67. Hikma Pharmaceuticals Plc Business Overview Table 68. Hikma Pharmaceuticals Plc Vaginal Fungi Infections Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Hikma Pharmaceuticals Plc Vaginal Fungi Infections Treatment Product Portfolio Table 70. Hikma Pharmaceuticals Plc Recent Development Table 71. Lupin Limited Company Information Table 72. Lupin Limited Business Overview Table 73. Lupin Limited Vaginal Fungi Infections Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Lupin Limited Vaginal Fungi Infections Treatment Product Portfolio Table 75. Lupin Limited Recent Development Table 76. Mycovia Pharmaceuticals Company Information Table 77. Mycovia Pharmaceuticals Business Overview Table 78. Mycovia Pharmaceuticals Vaginal Fungi Infections Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Mycovia Pharmaceuticals Vaginal Fungi Infections Treatment Product Portfolio Table 80. Mycovia Pharmaceuticals Recent Development Table 81. PEPTONIC medical AB Company Information Table 82. PEPTONIC medical AB Business Overview Table 83. PEPTONIC medical AB Vaginal Fungi Infections Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. PEPTONIC medical AB Vaginal Fungi Infections Treatment Product Portfolio Table 85. PEPTONIC medical AB Recent Development Table 86. SCYNEXIS Company Information Table 87. SCYNEXIS Business Overview Table 88. SCYNEXIS Vaginal Fungi Infections Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. SCYNEXIS Vaginal Fungi Infections Treatment Product Portfolio Table 90. SCYNEXIS Recent Development Table 91. Unique Pharmaceuticals Company Information Table 92. Unique Pharmaceuticals Business Overview Table 93. Unique Pharmaceuticals Vaginal Fungi Infections Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Unique Pharmaceuticals Vaginal Fungi Infections Treatment Product Portfolio Table 95. Unique Pharmaceuticals Recent Development Table 96. Pfizer Inc. Company Information Table 97. Pfizer Inc. Business Overview Table 98. Pfizer Inc. Vaginal Fungi Infections Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Pfizer Inc. Vaginal Fungi Infections Treatment Product Portfolio Table 100. Pfizer Inc. Recent Development Table 101. Research Programs/Design for This Report Table 102. Authors List of This Report Table 103. Secondary Sources Table 104. Primary Sources List of Figures Figure 1. Vaginal Fungi Infections Treatment Product Image Figure 2. Global Vaginal Fungi Infections Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vaginal Fungi Infections Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Vaginal Fungi Infections Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Flucytosine Image Figure 8. Fluconazole Image Figure 9. Nystatin Image Figure 10. Others Image Figure 11. Global Vaginal Fungi Infections Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Vaginal Fungi Infections Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Vaginal Fungi Infections Treatment Sales Value Share by Type (2021-2032) Figure 14. Hospital Pharmacies Image Figure 15. Online Pharmacies Image Figure 16. Retail Pharmacies Image Figure 17. Global Vaginal Fungi Infections Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Vaginal Fungi Infections Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Vaginal Fungi Infections Treatment Sales Value Share by Application (2021-2032) Figure 20. Global Vaginal Fungi Infections Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Vaginal Fungi Infections Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Vaginal Fungi Infections Treatment Sales Value (2021-2032) & (US$ Million) Figure 23. North America Vaginal Fungi Infections Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Vaginal Fungi Infections Treatment Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Vaginal Fungi Infections Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Vaginal Fungi Infections Treatment Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Vaginal Fungi Infections Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Vaginal Fungi Infections Treatment Sales Value (2021-2032) & (US$ Million) Figure 29. South America Vaginal Fungi Infections Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Vaginal Fungi Infections Treatment Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Vaginal Fungi Infections Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Flucytosine
  • Fluconazole
  • Nystatin
  • Others
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • ANI Pharmaceuticals
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc
  • Dr. Reddy's Laboratories
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals Plc
  • Lupin Limited
  • Mycovia Pharmaceuticals
  • PEPTONIC medical AB
  • SCYNEXIS
  • Unique Pharmaceuticals
  • Pfizer Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Vaginal Fungi Infections Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Vaginal Fungi Infections Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Vaginal Fungi Infections Treatment Market Dynamics
  1. 2.1 Vaginal Fungi Infections Treatment Industry Trends
  2. 2.2 Vaginal Fungi Infections Treatment Industry Drivers
  3. 2.3 Vaginal Fungi Infections Treatment Industry Opportunities and Challenges
  4. 2.4 Vaginal Fungi Infections Treatment Industry Restraints
3 Vaginal Fungi Infections Treatment Market by Company
  1. 3.1 Global Vaginal Fungi Infections Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Vaginal Fungi Infections Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Vaginal Fungi Infections Treatment Company Ranking (2024-2026)
  4. 3.4 Global Vaginal Fungi Infections Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Vaginal Fungi Infections Treatment Company Product Type and Application
  6. 3.6 Global Vaginal Fungi Infections Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Vaginal Fungi Infections Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Vaginal Fungi Infections Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Vaginal Fungi Infections Treatment Market by Type
  1. 4.1 Vaginal Fungi Infections Treatment Type Introduction
  2. 4.1.1 Flucytosine
  3. 4.1.2 Fluconazole
  4. 4.1.3 Nystatin
  5. 4.1.4 Others
  6. 4.2 Global Vaginal Fungi Infections Treatment Sales Value by Type
  7. 4.2.1 Global Vaginal Fungi Infections Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Vaginal Fungi Infections Treatment Sales Value by Type (2021-2032)
  9. 4.2.3 Global Vaginal Fungi Infections Treatment Sales Value Share by Type (2021-2032)
5 Vaginal Fungi Infections Treatment Market by Application
  1. 5.1 Vaginal Fungi Infections Treatment Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Vaginal Fungi Infections Treatment Sales Value by Application
  6. 5.2.1 Global Vaginal Fungi Infections Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Vaginal Fungi Infections Treatment Sales Value by Application (2021-2032)
  8. 5.2.3 Global Vaginal Fungi Infections Treatment Sales Value Share by Application (2021-2032)
6 Vaginal Fungi Infections Treatment Regional Value Analysis
  1. 6.1 Global Vaginal Fungi Infections Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vaginal Fungi Infections Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Vaginal Fungi Infections Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Vaginal Fungi Infections Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Vaginal Fungi Infections Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Vaginal Fungi Infections Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Vaginal Fungi Infections Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Vaginal Fungi Infections Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Vaginal Fungi Infections Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Vaginal Fungi Infections Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Vaginal Fungi Infections Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Vaginal Fungi Infections Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Vaginal Fungi Infections Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Vaginal Fungi Infections Treatment Sales Value Share by Country, 2025 VS 2032
7 Vaginal Fungi Infections Treatment Country-level Value Analysis
  1. 7.1 Global Vaginal Fungi Infections Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Vaginal Fungi Infections Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Vaginal Fungi Infections Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Vaginal Fungi Infections Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Vaginal Fungi Infections Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Vaginal Fungi Infections Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Vaginal Fungi Infections Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 ANI Pharmaceuticals
  2. 8.1.1 ANI Pharmaceuticals Company Information
  3. 8.1.2 ANI Pharmaceuticals Business Overview
  4. 8.1.3 ANI Pharmaceuticals Vaginal Fungi Infections Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 ANI Pharmaceuticals Vaginal Fungi Infections Treatment Product Portfolio
  6. 8.1.5 ANI Pharmaceuticals Recent Developments
  7. 8.2 Aurobindo Pharma Limited
  8. 8.2.1 Aurobindo Pharma Limited Company Information
  9. 8.2.2 Aurobindo Pharma Limited Business Overview
  10. 8.2.3 Aurobindo Pharma Limited Vaginal Fungi Infections Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Aurobindo Pharma Limited Vaginal Fungi Infections Treatment Product Portfolio
  12. 8.2.5 Aurobindo Pharma Limited Recent Developments
  13. 8.3 Bausch Health Companies Inc
  14. 8.3.1 Bausch Health Companies Inc Company Information
  15. 8.3.2 Bausch Health Companies Inc Business Overview
  16. 8.3.3 Bausch Health Companies Inc Vaginal Fungi Infections Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bausch Health Companies Inc Vaginal Fungi Infections Treatment Product Portfolio
  18. 8.3.5 Bausch Health Companies Inc Recent Developments
  19. 8.4 Dr. Reddy's Laboratories
  20. 8.4.1 Dr. Reddy's Laboratories Company Information
  21. 8.4.2 Dr. Reddy's Laboratories Business Overview
  22. 8.4.3 Dr. Reddy's Laboratories Vaginal Fungi Infections Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Dr. Reddy's Laboratories Vaginal Fungi Infections Treatment Product Portfolio
  24. 8.4.5 Dr. Reddy's Laboratories Recent Developments
  25. 8.5 Glenmark Pharmaceuticals Limited
  26. 8.5.1 Glenmark Pharmaceuticals Limited Company Information
  27. 8.5.2 Glenmark Pharmaceuticals Limited Business Overview
  28. 8.5.3 Glenmark Pharmaceuticals Limited Vaginal Fungi Infections Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Glenmark Pharmaceuticals Limited Vaginal Fungi Infections Treatment Product Portfolio
  30. 8.5.5 Glenmark Pharmaceuticals Limited Recent Developments
  31. 8.6 Hikma Pharmaceuticals Plc
  32. 8.6.1 Hikma Pharmaceuticals Plc Company Information
  33. 8.6.2 Hikma Pharmaceuticals Plc Business Overview
  34. 8.6.3 Hikma Pharmaceuticals Plc Vaginal Fungi Infections Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Hikma Pharmaceuticals Plc Vaginal Fungi Infections Treatment Product Portfolio
  36. 8.6.5 Hikma Pharmaceuticals Plc Recent Developments
  37. 8.7 Lupin Limited
  38. 8.7.1 Lupin Limited Company Information
  39. 8.7.2 Lupin Limited Business Overview
  40. 8.7.3 Lupin Limited Vaginal Fungi Infections Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Lupin Limited Vaginal Fungi Infections Treatment Product Portfolio
  42. 8.7.5 Lupin Limited Recent Developments
  43. 8.8 Mycovia Pharmaceuticals
  44. 8.8.1 Mycovia Pharmaceuticals Company Information
  45. 8.8.2 Mycovia Pharmaceuticals Business Overview
  46. 8.8.3 Mycovia Pharmaceuticals Vaginal Fungi Infections Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Mycovia Pharmaceuticals Vaginal Fungi Infections Treatment Product Portfolio
  48. 8.8.5 Mycovia Pharmaceuticals Recent Developments
  49. 8.9 PEPTONIC medical AB
  50. 8.9.1 PEPTONIC medical AB Company Information
  51. 8.9.2 PEPTONIC medical AB Business Overview
  52. 8.9.3 PEPTONIC medical AB Vaginal Fungi Infections Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 PEPTONIC medical AB Vaginal Fungi Infections Treatment Product Portfolio
  54. 8.9.5 PEPTONIC medical AB Recent Developments
  55. 8.10 SCYNEXIS
  56. 8.10.1 SCYNEXIS Company Information
  57. 8.10.2 SCYNEXIS Business Overview
  58. 8.10.3 SCYNEXIS Vaginal Fungi Infections Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 SCYNEXIS Vaginal Fungi Infections Treatment Product Portfolio
  60. 8.10.5 SCYNEXIS Recent Developments
  61. 8.11 Unique Pharmaceuticals
  62. 8.11.1 Unique Pharmaceuticals Company Information
  63. 8.11.2 Unique Pharmaceuticals Business Overview
  64. 8.11.3 Unique Pharmaceuticals Vaginal Fungi Infections Treatment Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Unique Pharmaceuticals Vaginal Fungi Infections Treatment Product Portfolio
  66. 8.11.5 Unique Pharmaceuticals Recent Developments
  67. 8.12 Pfizer Inc.
  68. 8.12.1 Pfizer Inc. Company Information
  69. 8.12.2 Pfizer Inc. Business Overview
  70. 8.12.3 Pfizer Inc. Vaginal Fungi Infections Treatment Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Pfizer Inc. Vaginal Fungi Infections Treatment Product Portfolio
  72. 8.12.5 Pfizer Inc. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst